Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac)

P. J. Burke, Judith Karp, R. B. Geller, W. P. Vaughan

Research output: Contribution to journalArticle

Abstract

A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a >40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensvie but nonablative treatment plans.

Original languageEnglish (US)
Pages (from-to)692-694
Number of pages3
JournalLeukemia
Volume3
Issue number10
StatePublished - 1989

Fingerprint

Leukemia
Disease-Free Survival
Bone Marrow
Daunorubicin
Cytarabine
Bone Marrow Transplantation
Acute Myeloid Leukemia
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Cures of leukemia with aggressive postremission treatment : An update of timed sequential therapy (Ac-D-Ac). / Burke, P. J.; Karp, Judith; Geller, R. B.; Vaughan, W. P.

In: Leukemia, Vol. 3, No. 10, 1989, p. 692-694.

Research output: Contribution to journalArticle

Burke, P. J. ; Karp, Judith ; Geller, R. B. ; Vaughan, W. P. / Cures of leukemia with aggressive postremission treatment : An update of timed sequential therapy (Ac-D-Ac). In: Leukemia. 1989 ; Vol. 3, No. 10. pp. 692-694.
@article{a59035e729e640679f5cd7778ab080eb,
title = "Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac)",
abstract = "A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a >40{\%} probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensvie but nonablative treatment plans.",
author = "Burke, {P. J.} and Judith Karp and Geller, {R. B.} and Vaughan, {W. P.}",
year = "1989",
language = "English (US)",
volume = "3",
pages = "692--694",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Cures of leukemia with aggressive postremission treatment

T2 - An update of timed sequential therapy (Ac-D-Ac)

AU - Burke, P. J.

AU - Karp, Judith

AU - Geller, R. B.

AU - Vaughan, W. P.

PY - 1989

Y1 - 1989

N2 - A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a >40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensvie but nonablative treatment plans.

AB - A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a >40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensvie but nonablative treatment plans.

UR - http://www.scopus.com/inward/record.url?scp=0024432752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024432752&partnerID=8YFLogxK

M3 - Article

C2 - 2674562

AN - SCOPUS:0024432752

VL - 3

SP - 692

EP - 694

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -